However, in common practice among medical physicists, "MIRD237" has become shorthand for the and S-value tables that underpin most commercial dosimetry software. The number "237" appears in legacy database entries, DICOM-RT headers, and internal code libraries used to calculate absorbed doses for radiopharmaceutical therapy (RPT).
Researchers are now integrating MIRD237 S-values into that predict dose from a single time-point scan. For example, a U-Net architecture trained on thousands of MIRD237 phantom simulations can estimate kidney dose from a single Lu-177 SPECT/CT acquired at 24 hours post-injection.
In essence, MIRD237 provides the pre-calculated nuclear decay data and geometric factors required to apply the : mird237
for the specific radionuclide, target region, and source region. For example, the S-value for "Kidney ← Liver" with Lu-177 is found in the MIRD237 lookup table.
If you have ever wondered how doctors determine exactly how much radiation a tumor will receive—or, more critically, how much a healthy organ like the liver or bone marrow will absorb—you have encountered the legacy of MIRD237. This article provides a comprehensive deep dive into what MIRD237 is, why it remains a cornerstone of dosimetry, and how it is evolving in the era of personalized theranostics. MIRD237 is the formal designation for a seminal publication by the Society of Nuclear Medicine (SNM) and the Medical Internal Radiation Dose (MIRD) Committee. Officially titled "MIRD Cellular S Values: Self-Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Cellular Models," MIRD237 (often referred to in shorthand as "MIRD Pamphlet No. 23" or the cellular S-value supplement) extended classical organ-level dosimetry into the microscopic domain. For example, a U-Net architecture trained on thousands
$$D = \tilde{A} \times S$$
from all source regions to each target region. If you have ever wondered how doctors determine
(SPECT/CT or PET/CT) at multiple time points after radiopharmaceutical administration.